(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 5.91% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Myriad Genetics's revenue in 2026 is $829,000,000.On average, 12 Wall Street analysts forecast MYGN's revenue for 2026 to be $83,188,094,404, with the lowest MYGN revenue forecast at $79,527,281,784, and the highest MYGN revenue forecast at $86,328,497,386. On average, 12 Wall Street analysts forecast MYGN's revenue for 2027 to be $88,133,402,679, with the lowest MYGN revenue forecast at $82,766,855,387, and the highest MYGN revenue forecast at $93,537,729,256.
In 2028, MYGN is forecast to generate $92,987,096,191 in revenue, with the lowest revenue forecast at $86,123,544,771 and the highest revenue forecast at $101,248,481,120.